Compare JF & IRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JF | IRIX |
|---|---|---|
| Founded | 2012 | 1989 |
| Country | China | United States |
| Employees | 30 | N/A |
| Industry | | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.5M | 18.2M |
| IPO Year | N/A | 1996 |
| Metric | JF | IRIX |
|---|---|---|
| Price | $1.02 | $1.06 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 7.9K | ★ 50.6K |
| Earning Date | 04-24-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 51.85 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,593,000.00 |
| Revenue This Year | N/A | $3.07 |
| Revenue Next Year | N/A | $6.66 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.89 | $0.87 |
| 52 Week High | $1.12 | $1.65 |
| Indicator | JF | IRIX |
|---|---|---|
| Relative Strength Index (RSI) | 52.69 | 50.53 |
| Support Level | $0.90 | $1.01 |
| Resistance Level | $1.09 | $1.18 |
| Average True Range (ATR) | 0.05 | 0.04 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 61.77 | 59.90 |
J and Friends Holdings Ltd providing merchant digitalization and commerce-enablement solutions to small and medium enterprises (SME). Its solutions feature critical functionality that SMEs need to engage with consumers, manage their operations, accept payments, and grow their business. Such solutions empower single- and multi-location retailers, restaurants, and other SMEs to compete successfully in an omni-channel market environment by engaging with consumers across online, mobile, and physical channels. The group conducts all of its current operations in Australia and generates revenues from continuing operations are derived from within Australia.
IRIDEX Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures used to treat sight-threatening eye conditions, including glaucoma and retinal diseases. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.